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Introduction
The AMP-activated protein kinase (AMPK), a serine/threonine kinase, is a highly conserved energy sensor that plays a central role in maintaining energy homeostasis by balancing catabolic and anabolic processes. 1 AMPK is activated under conditions of energy stress, primarily when the intracellular ATP: AMP ratio decreases (e.g., during nutrient deprivation or hypoxia).
2 AMPK exists as heterotrimeric complexes composed of a catalytic (a) subunit and 2 regulatory (b and g) subunits, each of which occurs as 2 or more isoforms encoded by distinct genes (a1, a2, b1, b2, g1, g2, g3). The expression of some of these isoforms is tissue-restricted, and functional distinctions have been reported for the 2 catalytic a subunits; i.e. AMPKa2 has a greater dependence on AMP than AMPKa1, and AMPKa2, but not AMPKa1, is localized to the nucleus. 3 Activation of AMPK requires phosphorylation of threonine 172 (Thr172) within the T loop of the catalytic a subunit. To date, 2 AMPK kinases have been characterized: the tumor suppressor, LKB1, and Ca 2C /calmodulin-dependent protein kinase kinase b (CaMKKb). 4 LKB1 is ubiquitously expressed and appears to be the principal kinase responsible for activating AMPK in response to metabolic stress in liver and skeletal muscle. [5] [6] [7] In contrast, the activation of AMPK by CaMKKb does not require alteration of the ATP:AMP ratio, but rather occurs in response to various cues, including increased intracellular Ca 2C . [8] [9] [10] CaMKKb seems to be particularly involved in activating AMPK in neurons and T cells. 11, 12 Recent studies have revealed that AMPK contributes to phenotypes other than maintaining energy homeostasis such as regulating cell polarity, mitotic progression, and cytokinesis. For example, studies in Drosophila have shown that disruption of AMPKa enhances cell proliferation and increases gross mitotic defects, such as lagging chromosome during anaphase, failure of cytokinesis and the acquisition of polyploidy. 13 In flies, AMPK mediates the Ser22 phosphorylation of non-muscle myosin regulatory light chain (MRLC), which interacts with actin to regulate the changes in the actin cytoskeleton that are required to maintain cell polarity. 13 In mammals, AMPK activity progressively increases as cells move from G1 phase toward the G2/M phases of the cell cycle.
14 During the mitotic phase, active AMPK has been observed to be transiently associated with several components of the mitotic apparatus, including spindle poles and the midbody. 15 In addition, a recent study identified novel targets of AMPK, including PAK2, APC1, CDC27, and 3 of the regulatory subunits (PPP1R12A, PPP1R12B, and PPP1R12C) that influence the activity of mammalian MRLC. 16 Thus, it is not surprising that depletion of AMPK causes mitotic delay, mis-orientation of the spindles, and reductions in the numbers and lengths of the astral microtubules. 17 In interphase mammalian cells, the Golgi apparatus is organized into a continuous membranous system; known as the Golgi ribbon, it is formed of individual Golgi stacks that are laterally connected by tubular bridges. 18 During mitosis, the Golgi ribbon undergoes extensive fragmentation through a multistage process that is required for its correct partitioning into daughter cells. 19 Unlinking of the Golgi stacks occur during G2 phase, and it is controlled by various kinases, including Raf1, MEK1, ERK2 and Plk3. [20] [21] [22] [23] These kinases can phosphorylate the Golgi reassembly stacking proteins, GRASP65 and GRASP55, which form a complex matrix that is involved in organizing the structure and function of the Golgi apparatus. 24, 25 Failure of Golgi fragmentation induces cell cycle arrest at G2 phase, which we call "Golgi mitotic checkpoint." 26 After the cell enters mitosis, the Golgi stacks undergo further disassembly through the actions of Plk1 and Cdk1, which phosphorylate the golgins (e.g., GM-130), and proteins involved in membrane fusion. [27] [28] [29] Interestingly, a recent study demonstrated that Golgi-specific brefeldin Aresistance guanine nucleotide exchange factor 1 (GBF1) is a novel AMPK substrate, and that the AMPK-mediated phosphorylation of GBF1 at Thr1337 plays a critical role (presumably by attenuating the function of GBF1) in the Golgi disassembly that is induced by stress conditions that lower the intracellular concentration of ATP. 30 Furthermore, another recent study showed that AMPK phosphorylates GBF1 for mitotic Golgi disassembly, and phosphorylationdefective mutant of GBF1 induces G2/M arrest, suggesting the involvement of AMPK in both Golgi disassembly and G2/M transition. 31 However, the precise mechanism has yet to be clarified.
In the present study, we explored the roles of AMPK during mitotic entry in HeLa cells. We show that AMPK is activated at late G2 phase, and that pAMPKa Thr172 signals increase in the perinuclear region, partially colocalizing with the Golgi marker, GM-130. Inhibition of AMPK or (more specifically) AMPKa2 depletion transiently arrests mitotic entry and delays mitotic Golgi fragmentation. Furthermore, CaMKKb inhibition decreases the pAMPKa Thr172 signals in the Golgi region and delays mitotic Golgi fragmentation. Our results collectively suggest that the CaMKKb-AMPKa2 signaling pathway is involved in regulating Golgi fragmentation during the G2/M transition.
Results

AMPKa is highly phosphorylated in the G2/M phases and localizes to the mitotic apparatus in HeLa cells
Recent studies have found that AMPK is phosphorylated during mitosis, and that during this time it is localized to components of the mitotic apparatus (e.g., centrosomes, mitotic spindle poles and the midbody), seemingly independent of the cellular energy status. 15 Based on these reports, we herein studied the mitotic role of AMPK. We first started from HeLa cells, which harbor a homozygous deletion of LKB1. To assess when AMPK is activated during cell cycle progression, we synchronized HeLa cells at the G1/S border by a double-thymidine block (DTB), and then collected cells that had been released for 0 (G1/S phase), 3 (S phase), or 8 (G2/M phase) hours (h). The cell cycle progression of these cells was monitored by flow cytometry using propidium iodide and pHH3 (S10) staining to monitor the mitotic status (Fig. 1A) . Consistent with previous reports, 14 the basal activity of AMPK measured by either pAMPKa Thr172 or the phosphorylation status of its substrate acetyl CoA carboxylase (ACC) and myosin regulatory light chain (MRLC) was high in G2/M phase cells (Fig. 1B, and Fig. S1A ). Notably, we observed essentially the same findings by using LKB1-intact cells, i.e., U2OS cells and A431 cells (Fig. S1A) . In addition, we observed that active pAMPKa Thr172 localized on the spindle poles during prophase and metaphase, and on the midbody during telophase (Fig. 1C) , which was also consistent with previous report. 15 The observation that Inhibition of AMPK activity induced multinucleated cells (Fig. S1C ) might be related with the localization on the midbody. These data show that AMPK is activated during G2/M phase, when it localizes to various components of the mitotic apparatus.
AMPK inhibitor-treated cells spend prolonged periods in G2 phase and enter mitosis at a reduced rate
To further ascertain the involvement of AMPK in mitotic entry and progression, we synchronized HeLa cells at the G1/S border using DTB according to the scheme shown in Figure 2A . In brief, HeLa cells were synchronized using DTB and treated with a pharmacological AMPK inhibitor (compound C, 32 final concentration 3 mM) at early G2 phase (6 h post-release). The cells were then harvested at various time points, and cell cycle progression was monitored by flow cytometry using propidium iodide staining ( Fig. 2B and C) . We found that compound Ctreated cells progressed through G2/M phase much more slowly than control cells. To dissect whether this was due to a delay in the G2/M transition and/or mitotic progression, we used acetoorcein staining to analyze the mitotic index. We found that the increase in the mitotic population was dramatically and dosedependently delayed in compound C-treated cells versus control cells (Fig. 2D) , indicating that the delay in G2/M progression mainly stemmed from a delay in the G2/M transition. To corroborate this finding, we further analyzed 2 mitotic markers, phosphorylation of histone H3 at serine 10 and degradation of cyclin B1, in control and compound C-treated cells (Fig. 2E) . In control cells, histone H3 phosphorylation was first detected 8 h Figure 1 . AMPKa is highly phosphorylated in G2/M phase and localized to mitotic apparatus. (A and B) HeLa cells were synchronized at the G1/S border by DTB and released for 0 h (G1/S phase), 3 h (S phase), and 8 h (G2/M). (A) Cells were fixed, stained with propidium iodide and phospho-histon H3 (S10) to visualize mitotic cells, and analyzed by flow cytometry. The percentages of mitotic cells in G1/S, S, and G2/M phases are indicated in dashed box. (B) Cells were lysed, and phosphorylation of AMPKa at threonine 172 and histone H3 at serine 10 was detected by Western blot analysis using specific antibodies. Detection of a-tubulin served as a loading control. Lysates were also analyzed using AMPKa1/2-and histone H3-specific antibodies to ensure that total protein levels were unchanged. Shown is a representative data from 3 independent experiments. (C) Localization pattern of pAMPKa Thr172 signals during mitosis. At 9 h after release from DTB, cells were fixed and stained for pAMPKa Thr172 for active AMPK, for g-tubulin to recognize the spindle poles and with DAPI to visualize the nucleus. Shown is a representative image from 3 independent experiments. Scale bar, 10 mm.
post-release; it peaked at 9 h post-release, and decreased at 11 and 12 h post-release. In contrast, compound C-treated cells displayed a weaker and delayed histone H3 phosphorylation, indicating the delay in the G2/M transition. Notably, histone H3 phosphorylation was still observed at 12 h post-release in compound C-treated cells, which is consistent with the observed delay in their mitotic progression. Since cyclin B1 level increases during G2 phase and decreases around anaphase onset, 33 delay in G2/M transition would result in normal increase, but delayed decrease of cyclin B1; it was the case as shown in Figure 2E . Inhibition of AMPK activity was confirmed by measuring substrate phosphorylation both in HeLa cells ( Fig. S2A ) and U2OS cells (Fig. S2B) . The delay in mitotic entry was also observed in U2OS cells ( Fig. S2C and D ) and A431 cells ( Fig. S3A and B) . These results indicate that pharmacological inhibition of AMPK delayed the G2/M transition, suggesting that AMPK could regulate mitotic entry.
Depletion of AMPKa2, but not AMPKa1, delays mitotic entry
In mammals, there are 2 catalytic subunits of the AMPKa (i.e., AMPKa1 and AMPKa2), which show different intracellular localization, and different responsiveness to AMP and LKB1. 3 To further investigate the potential mitotic roles of the 2 catalytic subunits, we used specific siRNAs to deplete AMPKa1 or AMPKa2, and monitored cell cycle progression. We found that the cell cycle progression of AMPKa1-depleted cells was unaltered compared to that of control cells, but AMPKa2-depleted cells (similar to compound C-treated cells) progressed through G2/M phase much more slowly than did control cells (Fig. 3A) . In a parallel approach, we determined the mitotic index of HeLa cells lacking AMPKa1 or -a2 at 9 h post-release. As shown in Figure 3B , the proportion of mitotic cells was significantly lower in AMPKa2-depleted cells than in control cells. This further confirmed that the slower progression of AMPKa2-depleted cells through G2/M phase stemmed from a delay in mitotic entry. Experiments using additional siRNAs against AMPKa1 and AMPKa2 yielded similar results (Fig. 3B) , excluding the possibility of off-target effects and proving the specificity of the utilized siRNAs. We also analyzed whether a dominant-negative form of AMPKa2 could delay mitotic entry. In line with the results of our knockdown experiments, we found that mitotic cells were significantly decreased in AMPKa2-DN-transfected cells compared with control cells (Fig. 3C) , indicating that the activity of AMPKa2 is necessary for mitotic entry. Western blot analysis of cells released from DTB also clearly showed that cells lacking AMPKa2 experienced delays in cyclin B1 degradation and in histone H3 (S10) phosphorylation (Fig. 3D) , providing additional evidence that the delay in G2/M phase progression was due to a delay in the G2/M transition. Knockdown of AMPKa1 clearly decreased pAMPKa signal and the phosphorylation of its substrates, ACC and MRLC as well, indicating that the extent of AMPKa1 knockdown was enough to significantly reduce the activity of this isoenzyme ( Fig. S4A and B) . Intriguingly, knockdown of AMPKa2 changed neither pAMPKa signal nor the phosphorylation of its substrates, indicating that pAMPKa2 may be actually a minor form of activated AMPK at the whole cell level comparing to pAMPKa1, which was consistent with the much higher pAMPKa signals from AMPKa1 comparing to AMPKa2 after IP-western blotting of each isoenzyme (Fig. S1B) . The delay in G2/M transition by depletion of AMPKa2, but not AMPKa1, was also observed in U2OS cells ( Fig. S4C and D) . Notably, the inhibitory phosphorylation of cdk1 at Tyr15, which controls mitotic entry and progression, was observed at later time points in AMPKa2-depleted cells compared to control cells (Fig. 3D) ; it is not yet known whether this is a cause or effect of the G2/M transition delay. Collectively, these results clearly suggest that AMPKa2, but not AMPKa1, is the catalytic subunit of AMPK that regulates the G2/M transition in mammalian cells.
AMPKa2 depletion delays mitotic Golgi fragmentation
Two checkpoints regulate the G2/M transition: the DNA damage checkpoint, and the Golgi mitotic checkpoint. The former plays a key role in maintaining chromosomal integrity by allowing cells to repair DNA damage before entering mitosis. To exclude the possibility that AMPK inhibition delays mitotic entry by inducing DNA damage, we assessed the activation of DNA damage signaling in our system by measuring the phosphorylation of histone H2A.X at Ser139 (a molecular marker of DNA double-strand breaks). We failed to detect increased H2A.X phosphorylation in either compound C-treated or AMPKa2-depleted cells compared with control cells (Fig. S5) , excluding the presence of DNA damage.
To ensure correct partitioning between daughter cells, Golgi membranes are dispersed by a 2-step fragmentation process that completely vesiculates the Golgi ribbon into small vesicles. 19 The first step of this fragmentation process occurs during G2 phase and is characterized by cleavage of the tubular bridges that connect adjacent stacks. The inhibition of proteins involved in ribbon cleavage has been shown to arrest cells in G2 phase, 26 and recent studies have demonstrated that GBF1 is a novel AMPK substrate, and that phosphorylation of GBF1 by AMPK is necessary for mitotic Golgi disassembly. 30, 31 To analyze whether AMPK is involved in mitotic Golgi fragmentation, we analyzed DTB-synchronized HeLa cells that were treated with compound C or transfected with siControl, siAMPKa1, or -a2. At 9 h post-release, the cells were fixed and processed for immunofluorescent analysis using antibodies against Cenp-F (to identify G2 phase cells) and GM-130 (to identify the Golgi apparatus). Inhibition of AMPK by compound C strongly reduced the proportion of G2 cells harboring a fragmented Golgi apparatus ( Fig. 4A  and B) . Furthermore, AMPKa2-depleted cells, but not AMPKa1-depleted cells, showed significant delays in mitotic Golgi fragmentation ( Fig. 4A and C) , suggesting that AMPKa2, but not AMPKa1, is the catalytic subunit of AMPK that contributes to mitotic Golgi fragmentation during G2 phase.
Active AMPKa signaling is increased during late G2 phase, when it partially localizes to fragmented Golgi vesicles Since inhibition of AMPK delayed mitotic Golgi fragmentation and induced transient G2/M arrest, we hypothesized that AMPK is activated during both G2 phase and mitosis. To test this, we enriched HeLa cells at G2/M phase (at 8 h post-release from DTB), co-stained them with propidium iodide (for DNA), pAMPKa Thr172 (for activated AMPK) and pHH3 (S10) (for mitotic cells), and performed flow cytometric analysis. As expected, >90% [D29.6/(29.6 C 2.9)] of mitotic cells showed active AMPK signal, but, strikingly, activation of AMPK was also observed in 70% [D50.6/(50.6 C 16.8)] of G2 phase cells (Fig. 5A) . Since this indicated that AMPK is activated in G2 phase cells, we further analyzed the localization of active AMPK in G2 phase cells. HeLa cells were enriched at G2/M phase (at 8 h post-release) and processed for immunofluorescent analysis using antibodies against cyclin B1 (for late G2 phase; we counted cyclin B1-positive attached cells with intact nuclei that may include a minute fraction of early prophase cells) and pAMPKa Thr172 (for active AMPK). Notably, the pAMPKa Thr172 signals were transiently increased in the perinuclear region of cyclin B1-positive G2 phase cells (Fig. 5B) , suggesting that it may be localized to the Golgi apparatus. Furthermore, the percentage of G2 phase cells containing pAMPKa Thr172 signals was significantly higher at 9 h postrelease compared to 6 h post-release, indicating that AMPK is activated during late G2 phase. To further analyze the localization of these pAMPKa Thr172 signals, we stained synchronized HeLa cells at G2/M phase, and used specific antibodies against pAMPKa Thr172 and GM-130 (to visualize the Golgi apparatus).
The pAMPKa
Thr172 signals partially co-localized with those of GM-130, and were higher in cells containing fragmented Golgi vesicles compared to those containing the stacked form ( Fig. 5C ; we also observed the signal at centrosome). The pAMPKa Thr172 signal was also observed at or near Golgi vesicles and centrosome by using different antibody (Santa Cruz, sc-101630), and was disappeared when the antibody was pre-incubated with blocking peptide (Fig. S6) , confirming the specificity of our observation. Moreover, depletion of AMPKa2, but not AMPKa1, robustly abolished pAMPKa signal from Golgi fragments (Fig. 5D) , clearly indicating that the Golgi pAMPKa Thr172 signal was mainly derived from AMPKa2. Although pAMPKa2 is a minor form of activated AMPK at the whole cell level during G2/M phases (Fig. S1B, Fig. S4A and B) , it seemed to specifically localize at or near Golgi and affect the Golgi fragmentation. On the other hand, centrosomal pAMPKa Thr172 signal, that was increased as centrosome matured (Fig. S7A) , was partially abolished by depletion of either isoenzyme (Fig. S7B) , indicating that both pAMPKa1 and pAMPKa2 are active at the centrosome. Taken together, these results suggest that activation of AMPKa2 increases during late G2/early prophase at or near the fragmented Golgi vesicles, and this spatio-temporal activation of specific isoenzyme seems to contribute to further fragmentation of Golgi vesicles, thus affects G2/M transition.
Inhibition of CaMKKb decreases the pAMPKa signal and delays both Golgi fragmentation and mitotic entry LKB1 and CaMKKb are known to phosphorylate AMPKa at Thr172. 4 Since HeLa cells harbor a homozygous deletion of LKB1, 34 and recent studies have shown that CaMKKb phosphorylates AMPKa during mitosis, 17 we investigated whether CaMKKb is an upstream kinase of active AMPK during the G2/ M transition and mitotic Golgi fragmentation. HeLa cells were treated with different concentrations of STO-609 (an inhibitor of CaMKKb; 0, 2.5, 5, or 10 mg/ml) for 3 h beginning at 6 h postrelease, and then subjected to Western blot analysis. As expected, STO-609 treatment significantly and dose-dependently decreased the pAMPKa Thr172 signals and the phosphorylation of its downstream targets, pACC and pMRLC (Fig. 6A) . U2OS cells showed the same results (Fig. S2B) . Furthermore, the pAMPKa Thr172 signals colocalized with GM-130 signals were clearly abolished by treatment with STO-609 (Fig. 6B) , which was consistent with a significant decrease of pAMPKa Thr172 signals by STO-609 treatment from membrane fraction (Fig. 6C) , and indicates that activation of AMPK at Golgi apparatus during G2/M phase is dependent on CaMKKb activity. Similar to our results in compound C-treated cells, STO-609-treated cells showed delayed mitotic Golgi fragmentation (Fig. 6D) , and progressed through G2/M phase much more slowly (Fig. 6E for HeLa cells; Fig. S2C and D for U2OS cells and Fig. S3 for A431 cells) compared to control cells. The mitotic index of cells treated with 10 mg/ml STO-609 was decreased to a level similar to that seen in cells treated with 3 mM compound C (Fig. 6E) , indicating a delay in the G2/M transition. Furthermore, CaMKKb-depleted cells by specific siRNA also showed significant delays in mitotic Golgi fragmentation (Fig. S8) . Taken together, these data suggest that CaMKKb activates AMPK during late G2 phase, and that both mitotic Golgi fragmentation and the G2/M transition are regulated by the CaMKKb-AMPK signaling pathway.
Discussion
The AMP-activated protein kinase (AMPK) is a sensor of cellular energy homeostasis and an important mediator of various cellular processes, including autophagy, cell polarity and cell growth. 1, 35 In particular, recent studies have demonstrated a crucial link between mitotic progression and AMPK activity. 14, 17 Through a chemical genetic screen, Banko et al. identified novel AMPKa2 substrates, and found that they were enriched in proteins related to cytoskeletal dynamics, mitosis and cytokinesis. 16 In mammalian cells, the active form of the catalytic AMPKa subunit has been directly associated with multiple mitotic structures during each stage of mitosis. 15 Here, we focused on the role of AMPK during the G2/M transition.
During mitosis, the Golgi apparatus undergoes extensive fragmentation via a multistage process that begins during G2 phase, when the Golgi ribbon is severed into its constituent stacks. Inhibition of mitotic Golgi fragmentation results in cell cycle arrest at G2 phase, suggesting that correct segregation of the Golgi Figure 3 (See previous page). Depletion of AMPKa2, but not AMPKa1, delays the mitotic entry. HeLa cells transfected with a control siRNA-, AMPKa1-, or AMPKa2-specific siRNAs were synchronized at the G1/S border by DTB and released for the indicated times. (A) Cells were fixed, stained with propidium iodide, and analyzed by flow cytometry. The percentages of cells in G1, S, and G2/M phases are indicated. (B) At 9 h after the release from DTB, cells were stained with aceto-orcein solution and mitotic cells were counted. Cells were lysed, and expression of AMPKa1 and AMPKa2 was analyzed by Western blot analysis using specific antibodies. Detection of GAPDH served as a loading control. ***, p < 0.001 by one-way ANOVA analysis. (C) HeLa cells transfected with pcDNA or AMPKa2-DN construct were synchronized at the G1/S border by DTB and released for 8 h before analysis. Cells were stained with aceto-orcein solution and mitotic cells were counted. Cells were also lysed, and expression of AMPKa2-DN construct was analyzed by Western blot analysis using specific antibodies. Detection of a-tubulin served as a loading control. ***, P < 0.001 by Student's t-test. (D) HeLa cells transfected with a control siRNA, or AMPKa2-specific siRNAs were synchronized at the G1/S border by DTB and released for the indicated times. Cells were lysed, and subjected to SDS-PAGE and immunoblot analysis using indicated antibodies. Detection of GAPDH served as a loading control.
apparatus is monitored by a "Golgi mitotic checkpoint." 19 Recent studies have addressed the question of how Golgi fragmentation is functionally connected to regulating mitotic entry. Blockade of Golgi fragmentation was found to impair the recruitment and centrosomal activation of aurora-A, which in turn impaired the first activation of Cdk1-cyclin B at the centrosome during early G2 phase. 36 This Golgi-dependent G2 block was not mediated by the known activators of aurora-A (i.e., Pak1, HEF1, Ajuba). Thus, further work is needed to clarify the responsible molecules and mechanisms. Despite the relative lack of knowledge, Golgi fragmentation has been regarded as a preriquisite for mitotic entry. Herein, we, for the first time, showed the involvement of CaMKKb-AMPKa2 axis in the regulation of Golgi Figure 4 . AMPKa2 knockdown induces the delay of mitotic Golgi fragmentation. HeLa cells were synchronized at the G1/S border by DTB and released for 6h (early G2 phase). After then, cells were treated with DMSO or compound C (final 3 mM) and collected after 3 h. In parallel, HeLa cells transfected with a control siRNA, AMPKa1-, or AMPKa2-specific siRNAs were synchronized at the G1/S border by DTB and collected after release for 9 h. (A) Cells were fixed and processed for immunofluorescence using antibodies against Cenp-F for G2 phase and GM-130 for the Golgi apparatus. Scale bar, 50 mm.
(B and C) The structure of the Golgi apparatus was analyzed by immunofluorescence analysis in which we counted the percentage of cells showing a fragmented or stacked Golgi apparatus among Cenp-F-positive G2 phase cells. More than 200 cells were counted for each condition. ***, p < 0.001 by one-way ANOVA analysis.
fragmentation. Since we observed the transient activation of AMPKa2 irrespective of the presence of LKB1, it is highly probable that CaMKKb, but not LKB1, mainly controls Golgi fragmentation through activating AMPKa2, which subsequently regulates G2/M transition of the cell cycle. Since the activity of CaMKKb is not regulated by energy status, [8] [9] [10] the regulation of Golgi fragmentation by CaMKKb-AMPKa2 axis at least partially explains the upstream of the previously proposed energy-independent role of AMPK during mitotic progression. 15 Considering the significant decrease of pAMPKa signal by STO-609 ( Fig. 6A and  C ; whole cell level and in both cytosol and membrane fraction), CaMKKb-AMPKa1 axis might also exist and regulate other mitotic processes reportedly regulated by AMPK. 17 Previously, CaMKKb-mediated phosphorylation of AMPK was shown to occur in response to increased intracellular Ca 2C in LKB1-deficient cells. 12 Green et al. demonstrated that CaMKKb and AMPK associate through their kinase domains; furthermore, CaMKKb must be in an active conformation to bind AMPK, but this is not required for its association with other substrates, such as CaMKIV. 45 These findings suggest that the signals responsible for modifying the activation status of CaMKKb may act as molecular switches to couple CaMKKb with AMPK-and/ or CaMK-dependent pathways. 44 The questions such as how the CaMKKb is activated during G2/M transition and whether it localizes at Golgi apparatus during this period are waiting to be addressed.
AMPK functions as a heterotrimer that consists of a catalytic a subunit (a1 or a2) and the regulatory subunits, b (b1 or b2) and g (g1, g2, or g3). Although the 2 AMPKa isoforms are highly homologous, multiple reports indicate that AMPKa1 and AMPKa2 have mutual and exclusive functions. 3 Regarding the role of AMPK during mitotic progression, Pinter and colleagues showed that the a2b2g2 heterotrimeric complex associates with the mitotic apparatus, 37 and Banko et al. identified novel AMPKa2 substrates that were enriched for proteins involved in cytoskeletal dynamics, mitosis and cytokinesis, 16 suggesting the possible roles of AMPKa2 during mitosis. We observed that both catalytic a subunits (a1 and a2) were activated during G2/ M phases, and AMPKa1, but bot AMPKa2, is a major activated form of AMPKa during this period (Fig. S1B) . Knockdown experiments further confirmed that AMPKa1 is a major activated form. Whereas depletion of AMPKa1 reduced pAMPKa, pACC and pMRLC significantly in G2/M phase cells, depletion of AMPKa2 did not affect their phosphorylation (Fig. S4A) .
Then, how did the depletion of AMPKa2, but not AMPKa1, delay Golgi fragmentation as well as mitotic entry (Fig. 3 and 4) ? Our observation that pAMPKa signals at or near Golgi fragments during early prophase was clearly decreased by knockdown of AMPKa2, but not AMPKa1, (Fig. 5D) clearly indicates the possibility that AMPKa2 is specifically and transiently activated at Golgi apparatus during late G2/ early prophase, and regulates Golgi fragmentation which affects G2/M transition. In contrast, as previously reported, AMPKa1 seems to regulate later events of mitosis, such as spindle pole formation, cleavage furrow formation, and completion of cytokinesis through phosphorylation of MRLC. 13, 16, 17 We suggest that these 2 isoforms of AMPKa are spatio-temporally and specifically regulated during G2/M phases, and their substrate specificity would contribute to their specific roles during this period of cell cycle.
What would be the mitotic Golgi substrate of AMPKa2? A recent study found that GBF1 is a substrate of AMPK, and that it is involved in regulating mitotic Golgi fragmentation, but this study did not specify the isoenzyme type. 31 Furthermore, the chemical genetic screening of Banko et al. identified a number of Golgi-associated proteins as substrates of AMPK, 16 suggesting that there are many Golgi substrates of AMPK that have not yet been fully investigated.
In conclusion, we herein propose that AMPKa2 is specifically activated at the Golgi apparatus of late G2/early prophase cells by CaMKKb, and the CaMKKb-AMPK complex contributes to mitotic Golgi fragmentation and the G2/M transition.
Materials and Methods
Antibodies, chemicals, and plasmids
The following antibodies were used: mouse monoclonal antibodies to a-tubulin (Abcam, ab7291), AMPKa1/2 (Cell signaling, 2603), AMPKa1 (R&D systems, AF3197), AMPKa2 (R&D systems, AF2850), pAMPKa (Cell signaling, 2535), pAMPKa (Santa Cruz, sc-101630), MRLC (Cell signaling, 3672), pMRLC (S19) (Cell signaling, 3671), pACC(S79) (Cell signaling, 3661), g-Tubulin (Sigma, T6557), Cyclin B1 (Santa Cruz, sc-245), phospho-histone H3(S10) (Cell signaling, 9706), Cdk1-pY15(Cell Thr172 was detected by Western blot analysis. Detection of AMPKa1/2 served as a loading control to ensure that total protein levels were unchanged. Shown is a representative data from 3 independent experiments. (B) At 6 h after the release, cells were treated with DMSO or STO-609 (10mg/ml) and collected after 3 h. The cells were then fixed and processed for immunofluorescence using antibody against GM-130 or pAMPKa Thr172 . The calculation of pAMPKa Thr172 intensity at Golgi apparatus was performed as described in the legend for Fig. 5D . More than 20 cells were analyzed. **, P < 0.01 by Student's ttest. Scale bar, 10 mm. (C) The cytosol or the membrane fraction proteins were isolated from DMSO or STO-609 (10 mg/ml) treated cells and immunoblotted with the indicated antibodies. (D) At 8 h after the release, cells were fixed and processed for immunofluorescence using antibodies against Cenp-F for G2 phase and GM-130 for the Golgi apparatus. The structure of the Golgi apparatus was analyzed by immunofluorescence analysis in which we counted the percentage of cells showing the stacked Golgi apparatus among Cenp-F-positive G2 phase cells. More than 500 cells were counted for each condition. Scale bar, 50 mm. **, P < 0.01 by one-way ANOVA analysis. (E) At 6 h after the release, cells were treated with DMSO, compound C (final 3 mM), or STO-609 (10 mg/ml) and released for the indicated times. Cells were fixed, stained with propidium iodide, and analyzed by flow cytometry. At 9 h after the release, cells were stained with aceto-orcein solution and mitotic cells were counted. ***, P < 0.001 by one-way ANOVA analysis.
Cy5 (Invitrogen, A10524) and anti-mouse Cy3 (Jackson ImmunoResearch, 715-165-151). The AMPK inhibitor Compound C (171260) was obtained from CalBiochem, and CaMKKb inhibitor STO-609 (S1313) was from Sigma-Aldrich. Protease inhibitors, phosphatase inhibitors and other reagents were purchased from Sigma-Aldrich. The AMPKa2-DN mutant construct was generously provided by Prof. Joohun Ha (Kyung Hee University, Seoul, Republic of Korea). 38 Cell culture and synchronization by double-thymidine treatment HeLa cells were maintained in MEM (Welgene, LM007-01) supplemented with 10% (v/v) fetal bovine serum (Gibco, 16000-044) in 37 C incubator with 5% CO 2 in air. HeLa cells were synchronized at the G1/S border using a double-thymidine block. In brief, cells grown on culture dishes or coverslips were incubated in growth medium containing 1 mM thymidine (Sigma, T9250) for 18 h. Afterward, cells were released from the thymidine block by washing with serum-free medium and were cultured in growth medium for 9h. Subsequently, cells were subjected to the second thymidine block for an additional 16 h. After the second release, cells were collected at distinct time points. For inhibition of AMPK or CaMKKb, each inhibitor (compound C or STO-609) was treated at 6 h after DTB release (early G2 phase) and collected after 3 h.
Transfection experiment
HeLa cells were transfected with siRNAs using Oligofectamine (Invitrogen, 58303), according to manufacturer's instruction. Plasmid transfection was performed using Lipofectamine 2000 (Invitrogen, 52887), according to manufacturer's instruction. The siRNAs were purchased from Ambion. The sequences of the sense strands of the siRNA were as follows: 2 siRNAs for AMPKa1, 5 0 -GGUUGGCAAACAUGAAUUCdTdT-3 0 ; 5 0 -CUGAGUUGCAUAUACUGUA-dTdT-3 0 , 2 siRNAs for AMPKa2, 5 0 -GGUUUCUUAAAAACAGCUGdTdT-3 0 ; 5 0 -GGCCAUAAAGUGGCAGUUAdTdT-3 0 .
Immunoblotting
Conventional immunoblotting was performed as previously described using indicated antibodies. 39 Briefly, cells were washed in PBS and lysed in lysis solution [20 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, 5 mM NaF, 0.5 mM Na 3 VO 4 , 1 mg/ml Leupeptin, 1mg/ml Aprotinin]. The lysate was resuspended in Laemmli sample buffer and boiled for 5 min. The samples were separated by SDS-PAGE and then were transferred to PVDF membrane. After blocking for 1 h at room temperature with blocking solution [PBS containing 0.05% (V/V) Tween-20 and 5% (w/v) non-fat milk], the membranes were incubated at 4 C with indicated antibodies. Membranes were then washed 3 times with PBS containing 0.05% Tween-20 and incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibody for 1 h at room temperature. Detection was carried out using ECL reagents (Amersham Biosciences, RPN2106) and by exposing them to x-ray film.
Preparation of cell membrane fractions
Cell membrane fractions were separated as described previously. 40 In brief, cells were lysed in extracting buffer containing 10 mM Hepes, pH 7.4, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM DTT, 0.2 mM sodium orthovanadate, 1 mM NaF, and 0.5 mM PMSF, followed by incubation on ice for 15 min. Then, cells were passed through a 26-gauge needle 10 times and the homogenate was centrifuged at 14,000 rpm for 1 min to separate the nuclei from the cytosolic and membrane proteins in the cytoplasmic supernatant. The nuclei-free cytoplasmic supernatant was further centrifuged for 1.5 h at 50,000 rpm at 4 C. The supernatant fractions were saved as the cytosol proteins. The pellets containing membrane proteins were re-extracted with SDS-PAGE sample buffer and subjected to protein gel blot analysis.
Immunofluorescence analysis HeLa cells were grown on coverslips, washed with PBS, and fixed with ice-cold methanol for 10 min at ¡20
C. Fixed cells were pre-incubated in blocking solution (1% BSA in PBS) and incubated with primary antibodies diluted in blocking buffer (1:200) for overnight at 4 C. Cells were then washed and probed with fluorescence-conjugated secondary antibody for 1 h at room temperature. For DNA counterstaining, DAPI (Molecular probes, D3571) was used. After washing, cells were mounted in the mounting solution and analyzed on a confocal microscope (LSM710, Carl Zeiss).
Quantification of pAMPKa intensity and statistical analysis Z-series stacks of images at 0.44 mm intervals through each cell were obtained using a Zeiss LSM-710 confocal microscope. For quantification, all images were acquired at identical settings. Early prophase cells were randomly selected and analyzed for fluorescence intensity. To calculate pAMPKa Thr172 intensity, the mean intensity and areas of pAMPKa Thr172 signal from projected images with equal threshold were measured. The pAMPKa Thr172 intensity (AU) showed was calculated by multiplication of mean intensity by area. More than 20 cells were analyzed per one sample. Statistical analysis was performed by using the unpaired student's t-test in Excel (Microsoft, Redmond, WA) or one-way ANOVA analysis in R software (www.r-project.org).
Cell cycle analysis by flow cytometry Trypsinized cells were pelleted, washed in cold phosphate-buffered saline (PBS), and fixed in ice-cold 1% paraformaldehyde for 30 min at 4 C. Cells were washed in ice-cold PBS, resuspended in 90% ice-cold methanol, and incubated overnight at ¡20 C. Cells were subsequently washed, blocked with blocking solution (1% BSA in PBS) for 30 min, and incubated with the primary antibodies diluted in blocking buffer (1:100) for 2h. The cells were washed and incubated with fluorescence-conjugated secondary antibodies diluted in blocking buffer (1:200) for 1 h. The cells were washed and incubated with 50 mg/ml propidium iodide (Sigma, P4170) containing RNase A (Sigma, R4875) for 10 min. The cells were analyzed with a FACSCanto II flow cytometer (Becton Dickinson). Data were plotted with WinMDI software. Ten thousand events were analyzed for each sample.
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